Demographics
| n | CD | IBDU | UC | |
| 54 | 4 | 36 | ||
| Age | 42.2 (37.9–46.5) | 49.8 (28.4–71.1) | 43.1 (37.0–49.2) | |
| Gender | Female | 25 (46.3) | 2 (50.0) | 19 (52.8) |
| BMI | <18.5 | 6 (11.1) | 1 (25.0) | 3 (8.3) |
| 18.5–25 | 28 (51.9) | 2 (50) | 16 (44.4) | |
| 25–30 | 13 (24.1) | 1 (25) | 14 (38.9) | |
| >30 | 7 (13.0) | 0 (0.0) | 3 (8.3) | |
| MUST score | 0 | 17 (31.5) | 1 (25.0) | 17 (48.6) |
| 1 | 13 (24.1) | 1 (25.0) | 10 (28.6) | |
| 2 | 13 (24.1) | 2 (50.0) | 4 (11.4) | |
| ≥3 | 11 (20.4) | 0 (0.0) | 4 (11.4) | |
| Length of diagnosis (years) | 7.3 (4.6–10.0) | 3.3 (0–8.4) | 5.0 (3.2–6.8) | |
| History of diabetes | No | 49 (90.7) | 4 (100.0) | 35 (97.2) |
| Type 2 DM | 5 (9.3) | 0 (0.0) | 1 (2.8) | |
| Admission HbA1c | 38.5 (35.5–41.5) | 37.0 (33.1–40.8) | 37.7 (35.8–39.6) | |
| Admission calprotectin | 2854 (1980–2298) | 2491 (NA) | 3159 (2302–4071) | |
| Admission CRP | 75.9 (50.5–101.3) | 138.0 (106.7–169.3) | 88.9 (53.6–124.1) | |
| PMS | – | 5.50 (4.5–6.5) | 7.78 (7.2–8.3) | |
| HBI | 14.7 (13.0–16.5) | – | – | |
| Current treatment | Oral steroids | 8 (14.8) | 1 (25) | 6 (16.7) |
| Oral 5ASA | 2 (3.7) | 2 (50) | 20 (55.6) | |
| Immunomodulator | 18 (33.3) | 0 (0) | 6 (16.7) | |
| Anti-TNF | 10 (19.2) | 0 (0) | 10 (29.4) | |
| Vedolizumab | 2 (3.8) | 0 (0) | 0 (0.0) | |
| Ustekinumab | 7 (13.5) | 0 (0) | 0 (0.0) | |
| Smoking | Current | 12 (23.5) | 0 (0) | 0 (0.0) |
| Ex-smoker | 9 (17.7) | 1 (25.0) | 13 (36.1) | |
| Never smoked | 30 (58.8) | 3 (75.0) | 23 (63.9) |
For categorical variables n (%) shown, for continuous variables mean (95% CI) shown.’
anti-TNF, anti-tumour necrosis factor; 5-ASA, 5-aminosalicylic acid; BMI, body mass index; CRP, C-reactive protein; DM, diabetes mellitus; HbA1c, glycated haemoglobin; HBI, Harvey Bradshaw Index; IBDU, inflammatory bowel disease-as yet unclassified; MUST, Malnutrition Universal Screening Tool; PMS, Partial Mayo Score.